Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CG Oncology, Inc. ( (CGON) ) has issued an announcement.
CG Oncology, Inc. announced that its Chief Financial Officer, Corleen Roche, has resigned, with her departure effective on August 5, 2025. The company has appointed Robert Lapetina as the interim principal financial and accounting officer, effective the same date, until a permanent replacement is found.
The most recent analyst rating on (CGON) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology, Inc.’s overall stock score is bolstered by positive corporate developments in its clinical trials, which enhance future growth prospects. However, the score is tempered by ongoing financial challenges and reliance on external funding. Technical indicators suggest moderate momentum, though the lack of revenue and negative valuation metrics remain concerning.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
Average Trading Volume: 1,261,573
Technical Sentiment Signal: Sell
Current Market Cap: $2.06B
See more insights into CGON stock on TipRanks’ Stock Analysis page.